摘要
目的比较缬沙坦联合螺内酯与单用缬沙坦对原发性高血压合并阵发性心房颤动患者的临床疗效。方法选择74例原发性高血压(1,2级)合并阵发性心房颤动患者,均给予苯磺酸氨氯地平基础降压治疗后,随机分为缬沙坦联合螺内酯组,每日口服缬沙坦80mg￣160mg,螺内酯40mg;缬沙坦组,每日口服缬沙坦80mg￣160mg。观察9个月,比较治疗前后左房内径大小与房颤发作次数。结果治疗后两组左房内径较治疗前无明显差异(P>0.05);治疗6个月￣9个月后房颤发作次数较治疗前减少(P<0.05),但缬沙坦联合螺内酯组更为有效(P<0.01)。结论应用缬沙坦可延缓高血压并阵发性心房颤动患者左房扩大,防止房颤发作,联合螺内酯预防房颤发作效果更明显。
Objective To study the effects of Valsartan combined with Spironolactone on Paroxysmal Atrial Fibrillation （PAF） in patients with mild to moderate Essential Hypertension （EH）. Methods Seventy-four patients of mild to moderate EH with PAF were randomized to Valsartan plus Spironolactone group or Valsartan group. All the patients took Amlodipine Besylate per day orally. The patients in Valsartan plus Spironolactone group took Valsartan 80-160mg and Spironolactone 40mg per day orally; The patients in Valsartan group took Valsartan 80-160mg per day orally. The inner diameter of left atrium and the onsets of Atrial Fibrillation （AF） were measured at before and after the therapeutic 3rd day, 6th, and 9th months. Results The inner diameter of left atrium in two groups were not significantly changed at the 9th month, the onsets of AF during the 6th-9th month were decreased compared with pre-treatment in two groups and decreased significantly in Valsartan plus Spironolactone group. Conclusion Valsartan can prevent the enlargement of left atrium of patients with EH complicated with PAF. and reduce the onsets of AF, but the effect of valsartan combined with Spironolactone is wore significant to reduce the on- sets of AF.
出处
《实用心脑肺血管病杂志》
2007年第9期662-664,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
原发性高血压
阵发性心房颤动
缬沙坦
螺内酯
Essential Hypertension
Paroxysmal atrial fibrillation
Valsartan
Spironolactone
